Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Pancreatic Neoplasms

abstract

  • © 2015 Elsevier Inc. Pancreas adenocarcinoma is an aggressive malignancy. The risk of recurrence remains high even for patients with localized disease undergoing surgical resection. Adjuvant systemic therapy has demonstrated the ability to reduce the risk of recurrence and prolong survival. Determination of optimal adjuvant treatment, systemic therapy, and/or combinations to further improve recurrence rates and overall survival are still needed. Neoadjuvant therapy represents an alternative emerging paradigm of investigation with several theoretic advantages over adjuvant therapy. This article summarizes the major adjuvant and neoadjuvant studies for pancreas adenocarcinoma and highlights key areas of ongoing investigation.

publication date

  • January 2016

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.soc.2015.11.010

PubMed ID

  • 27013366

Additional Document Info